ArticleBiological psychiatry2020
Imaging Brain Fatty Acid Amide Hydrolase in Untreated Patients With Psychosis.
Article in Biological psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 28 citations in OpenAlex.
- PET Molecular Imaging of the Endocannabinoid System in Psychiatric Disorders.Neuroscience bulletin · 2026Review
- The Role of Fatty Acid Amide Hydrolase, a Key Regulatory Endocannabinoid Enzyme, in Domain-Specific Cognitive Performance in Psychosis.Schizophrenia bulletin · 2025Article
- Novel Lipid Formulation Increases Absorption of Oral Cannabidiol (CBD).Pharmaceutics · 2024Article
- The neurobiology of duration of untreated psychosis: a comprehensive review.Molecular psychiatry · 2023Review
- In vivo brain endocannabinoid metabolism is related to hippocampus glutamate and structure - a multimodal imaging study with PET,Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022Article
- Cannabidiol (CBD) as a novel treatment in the early phases of psychosis.Psychopharmacology · 2022Review
- Article
- Endocannabinoid system in psychotic and mood disorders, a review of human studies.Progress in neuro-psychopharmacology & biological psychiatry · 2021Review
- Lower amygdala fatty acid amide hydrolase in violent offenders with antisocial personality disorder: an [Translational psychiatry · 2021Article
- Positron Emission Tomography Imaging of the Endocannabinoid System: Opportunities and Challenges in Radiotracer Development.Journal of medicinal chemistry · 2021Review
- The Endocannabinoid System as Modulator of Exercise Benefits in Mental Health.Current neuropharmacology · 2021Review
Corrections and comments
- Commented on by
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThe brain's endocannabinoid system, the primary target of cannabis, has been implicated in psychosis. The endocannabinoid anandamide is elevated in cerebrospinal fluid of patients with schizophrenia. Fatty acid amide hydrolase (FAAH) controls brain anandamide levels; however, it is unknown if FAAH is altered in vivo in psychosis or related to positive psychotic symptoms.
methodsTwenty-seven patients with schizophrenia spectrum disorders and 36 healthy control subjects completed high-resolution positron emission tomography scans with the novel FAAH radioligand [
resultsFAAH did not differ significantly between patients with psychotic disorders and healthy control subjects (F
conclusionsThis first study of brain FAAH in psychosis indicates that FAAH may represent a biomarker of disease state of potential utility for clinical studies targeting psychotic symptoms or as a novel target for interventions to treat psychotic symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.